Chugai Says Sefaxersen Significantly Reduces Proteinuria in Phase III IgA Nephropathy Trial

Bitget2026/10/26 07:45

By:Bitget

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Chugai Pharmaceutical announced on October 26, 2026, that Roche’s sefaxersen significantly reduced proteinuria in patients with IgA nephropathy.
Roche released interim Phase III IMAgINATION findings on October 23. Results were presented at ASN Kidney Week 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chugai Pharmaceutical Co. Ltd. published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Chugai Says Sefaxersen Significantly Reduces Proteinuria in Phase III IgA Nephropathy Trial

You may also like

Crypto prices